Selinexor with R-GDP for lymphoma with TP53 change
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether adding a drug called selinexor to a standard chemo-immunotherapy combination (called R-GDP) can help people whose large B-cell lymphoma has a TP53 gene change and has not responded to earlier treatment. The goal is to see if this combination helps control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have diffuse large B-cell lymphoma (or a slow-growing lymphoma that has changed into this type) and your tumor has a change in a gene called TP53.
- You have had between 1 and 3 prior treatments for your lymphoma, but the last treatment didn’t work or the lymphoma came back.
- You have lymphoma that is measurable on a PET or CT scan (at least one lymph node larger than half an inch, or a spot outside the lymph nodes larger than about a third of an inch).
- Your blood counts, liver, and kidney function are good enough (specific numbers will be checked by the study team).
- You are willing to use effective birth control during the study and for 12 months after the last dose (if you or your partner can become pregnant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, glofitamab and selinexor, for patients with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two previous treatments. The goal is to see if this combination can help control the cancer.
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
This trial tests a combination of three drugs (selinexor, high-dose methotrexate, and rituximab) plus radiation for people with newly diagnosed central nervous system (CNS) lymphoma who cannot have a stem cell transplant. The goal is to see if this treatment can help control the cancer.
This study is testing whether a treatment chosen based on your tumor's genetic makeup works better than a standard one for people newly diagnosed with peripheral T-cell lymphoma. The goal is to find a more personalized approach that targets your specific cancer.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This trial uses a genetic test on your lymphoma tissue to help choose your treatment. It may help personalize therapy for people with newly diagnosed peripheral T-cell lymphoma and see how well the approach works and is tolerated.
Hear when a new Relapsed or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.